Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice
暂无分享,去创建一个
John Sharkey | Paul A. Jones | V. Buchman | Natalia Ninkina | P. Jones | Darren C. Robertson | Oliver Schmidt | Vladimir L. Buchman | J. Sharkey | O. Schmidt | N. Ninkina | D. C. Robertson
[1] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[2] Virginia M. Y. Lee,et al. Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.
[3] Makoto Hashimoto,et al. Development of a new treatment for alzheimer’s disease and parkinson’s disease using anti-aggregatory β-synuclein-derived peptides , 2002, Journal of Molecular Neuroscience.
[4] P. Brundin,et al. Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.
[5] V. P. Whittaker,et al. The Synaptic Vesicle , 1984 .
[6] Junying Yuan,et al. Releasing the nerve cell killers , 2002, Nature Medicine.
[7] A. Björklund,et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[8] A. Dehejia,et al. Identification, localization and characterization of the human γ-synuclein gene , 1998, Human Genetics.
[9] P. Lansbury,et al. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. , 2002, Biochemistry.
[10] M. Abercrombie. Estimation of nuclear population from microtome sections , 1946, The Anatomical record.
[11] Sebastian Doniach,et al. Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.
[12] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[13] Seung-Jae Lee. α-Synuclein Aggregation: A Link Between Mitochondrial Defects and Parkinson's Disease? , 2003 .
[14] C. Bruce,et al. Chaperone Suppression of a-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2002 .
[15] Howard J. Federoff,et al. Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.
[16] A. Björklund,et al. Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.
[17] M. Pericak-Vance,et al. Absence of Mutation in the β- and γ-Synuclein Genes in Familial Autosomal Dominant Parkinson's Disease , 1998 .
[18] R. Burke. Postnatal Developmental Programmed Cell Death in Dopamine Neurons , 2003, Annals of the New York Academy of Sciences.
[19] K. Prasad,et al. Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells , 2000, Brain Research.
[20] Johannes Schwarz,et al. Expression of mutant &agr;-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro , 2002, Neuroreport.
[21] J. Trojanowski,et al. Axon pathology in Parkinson ’ s disease and Lewy body dementia hippocampus contains a-, b-, and g-synuclein , 1999 .
[22] P. Lansbury,et al. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.
[23] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.
[24] Robert Burke,et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] Hitoshi Takahashi,et al. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.
[26] Jie Li,et al. The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.
[27] J. Powell,et al. Mutations in the gene encoding human persyn are not associated with amyotrophic lateral sclerosis or familial Parkinson's disease , 1999, Neuroscience Letters.
[28] A. Davies,et al. Induction of neuronal death by α‐synuclein , 2000, The European journal of neuroscience.
[29] R. Blakely,et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α‐synuclein , 2003, Journal of neurochemistry.
[30] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[31] M. Citron,et al. a-Synuclein Fibrillogenesis Is Nucleation-dependent IMPLICATIONS FOR THE PATHOGENESIS OF PARKINSON 9 S DISEASE , 1999 .
[32] J. Trojanowski,et al. Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease , 1999, Annals of neurology.
[33] F. Checler,et al. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. , 2002, The Journal of biological chemistry.
[34] R. Krüger,et al. Evaluation of the γ-synuclein gene in German Parkinson's disease patients , 2001, Neuroscience Letters.
[35] Kenji Ikeda,et al. Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein , 1999, Neuroscience Letters.
[36] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[37] Nigel J. Cairns,et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.
[38] L. Petrucelli,et al. α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.
[39] Hitoshi Takahashi,et al. Pick's disease: α- and β-synuclein-immunoreactive Pick bodies in the dentate gyrus , 2002, Acta Neuropathologica.
[40] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[41] M. Citron,et al. Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.
[42] J. Schaack,et al. Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture , 2002, Brain Research.
[43] R. Crowther,et al. a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies (ubiquitinysarkosyl-insoluble filamentsyimmunoelectron microscopy) , 1998 .
[44] J. Hardy,et al. Pathways to primary neurodegenerative disease. , 1999, Neurologia.
[45] Chaperones Take Flight , 2002, Science.
[46] E. Masliah,et al. C-terminal α-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders , 2000, Acta Neuropathologica.
[47] Vladimir N. Uversky,et al. Amino acid determinants of α‐synuclein aggregation: putting together pieces of the puzzle , 2002 .
[48] S. Helfand. Neurobiology. Chaperones take flight. , 2002, Science.
[49] Patrik Brundin,et al. Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.
[50] A. Davies,et al. Developmentally regulated expression of persyn, a member of the synuclein family, in skin. , 1999, Experimental cell research.
[51] E. Masliah,et al. α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .
[52] E. Masliah,et al. β-Synuclein Displays an Antiapoptotic p53-dependent Phenotype and Protects Neurons from 6-Hydroxydopamine-induced Caspase 3 Activation , 2003, Journal of Biological Chemistry.
[53] A. Davies,et al. Persyn, a Member of the Synuclein Family, Has a Distinct Pattern of Expression in the Developing Nervous System , 1998, The Journal of Neuroscience.
[54] Richard Paylor,et al. Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.
[55] Peter T Lansbury,et al. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. , 2003, Biochemistry.
[56] P. Lockhart,et al. Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.
[57] N. Bonini. Chaperoning brain degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[58] M. Citron,et al. α-Synuclein Fibrillogenesis Is Nucleation-dependent , 1999, The Journal of Biological Chemistry.
[59] V. Buchman,et al. Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.
[60] B. Hyman,et al. Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.
[61] A. Davies,et al. Neurons Expressing the Highest Levels of γ-Synuclein Are Unaffected by Targeted Inactivation of the Gene , 2003, Molecular and Cellular Biology.
[62] A. Dehejia,et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease , 1998, Molecular Psychiatry.
[63] L. Serpell,et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[64] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.
[65] T. Sherer,et al. Mechanistic Approaches to Parkinson's Disease Pathogenesis , 2002, Brain pathology.
[66] M. Citron,et al. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.
[67] P. Lansbury,et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.
[68] Smita Patel,et al. Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.
[69] A. Sidhu,et al. Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants , 2003, Neuroscience Letters.
[70] S. Totterdell,et al. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease , 2002, Brain Research.
[71] INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .
[72] Makoto Hashimoto,et al. β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.
[73] M. Vila,et al. α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.
[74] Z. Wang,et al. Parkinsonism proteolysis and proteasomes , 2002, Cell Death and Differentiation.
[75] D. Latchman,et al. Modulation of cell death by α-synuclein is stimulus-dependent in mammalian cells , 2003, Neuroscience Letters.
[76] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[77] J. Feldon,et al. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. , 2002, Journal of neurobiology.
[78] J. Trojanowski,et al. The Expression of α-, β-, and γ-Synucleins in Olfactory Mucosa from Patients with and without Neurodegenerative Diseases , 1999, Experimental Neurology.
[79] MoonHee Lee,et al. Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .
[80] G. Petzinger,et al. The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.
[81] J Q Trojanowski,et al. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[82] L. Greene,et al. Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.
[83] J. Trojanowski,et al. Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .
[84] Wenzhen Duan,et al. Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior , 2002, Neurobiology of Aging.
[85] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[86] A. Destée,et al. No pathogenic mutations in the persyn gene in Parkinson's disease , 1999, Neuroscience Letters.
[87] S. Kish,et al. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.
[88] P. Aebischer,et al. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[89] M. Cookson. Pathways to Parkinsonism , 2003, Neuron.
[90] J. Schulz,et al. Parkinson's disease: one biochemical pathway to fit all genes? , 2002, Trends in molecular medicine.
[91] C. Stichel,et al. The mouse MPTP model: gene expression changes in dopaminergic neurons , 2003, The European journal of neuroscience.
[92] L. Serpell,et al. Fiber diffraction of synthetic a-synuclein filaments shows amyloid-like cross-b conformation , 2000 .
[93] Olaf Riess,et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.
[94] T. Südhof,et al. Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice , 2003, Neuroscience.
[95] P. Lansbury,et al. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.
[96] J B Schulz,et al. Sensitivity to MPTP is not increased in Parkinson's disease‐associated mutant α‐synuclein transgenic mice , 2001, Journal of neurochemistry.
[97] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[98] A. Destée,et al. No pathogenic mutations in the β-synuclein gene in Parkinson's disease , 1999, Neuroscience Letters.
[99] Philippe Hantraye,et al. MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.
[100] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.